Metabolic signatures of hepatolithiasis using ultra-high performance liquid chromatography-tandem mass spectrometry

Wang, Cong; Yang, Jun; Li, Enliang; Luo, Shuaiwu; Sun, Chenguang; Liao, Yuting; Li, Min; Ge, Jian; Liu, Jun; Zhou, Fan; L, Wu; Liao, Wenjun

doi:10.1007/s11306-022-01927-2

Cited by 3 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolomic analyses observed that patients with hepatolithiasis have different serum levels of lipids and lipid-like molecules from healthy controls[ 38 ]. This reinforces previous findings that a dysregulated lipid metabolism is directly involved with the development of intrahepatic biliary stones[ 29 , 39 , 40 ].…”

Section: Pathophysiology and Risk Factorsmentioning

confidence: 99%

“…Biomarkers are not particularly useful for the diagnosis of hepatolithiasis. Recently, Wang et al [ 38 ] identified four metabolites, namely 18-β-Glycyrrhetinic acid, FMH, Rifampicin and PC (4:0/16:2), that are over-expressed in hepatolithiasis and had a good efficacy to discriminate patients with hepatolithiasis from healthy controls. However, the study only included 30 Chinese patients, thus these biomarkers need validation in larger and more heterogeneous populations before they are used in clinical practice.…”

Section: Investigationsmentioning

confidence: 99%

See 1 more Smart Citation

Hepatolithiasis: Epidemiology, presentation, classification and management of a complex disease

Motta,

Saffioti,

Mavroeidis

2024

World J Gastroenterol

View full text Add to dashboard Cite

The term hepatolithiasis describes the presence of biliary stones within the intrahepatic bile ducts, above the hilar confluence of the hepatic ducts. The disease is more prevalent in Asia, mainly owing to socioeconomic and dietary factors, as well as the prevalence of biliary parasites. In the last century, owing to migration, its global incidence has increased. The main pathophysiological mechanisms involve cholangitis, bile infection and biliary strictures, creating a self-sustaining cycle that perpetuates the disease, frequently characterised by recurrent episodes of bacterial infection referred to as syndrome of “recurrent pyogenic cholangitis”. Furthermore, long-standing hepatolithiasis is a known risk factor for development of intrahepatic cholangiocarcinoma. Various classifications have aimed at providing useful insight of clinically relevant aspects and guidance for treatment. The management of symptomatic patients and those with complications can be complex, and relies upon a multidisciplinary team of hepatologists, endoscopists, interventional radiologists and hepatobiliary surgeons, with the main goal being to offer relief from the clinical presentations and prevent the development of more serious complications. This comprehensive review provides insight on various aspects of hepatolithiasis, with a focus on epidemiology, new evidence on pathophysiology, most important clinical aspects, different classification systems and contemporary management.

show abstract

Section: Pathophysiology and Risk Factorsmentioning

confidence: 99%

Section: Investigationsmentioning

confidence: 99%

Hepatolithiasis: Epidemiology, presentation, classification and management of a complex disease

Motta,

Saffioti,

Mavroeidis

2024

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“… 474 LC-tandem MS was performed to characterize the serum metabolic signatures of hepatolithiasis, and identified 277 metabolites, AUC values for metabolites including18-β-glycyrrhetinic acid and PC (4:0/16:2) were up to 0.90, may have clinical value for hepatolithiasis. 475 A study showed that polyunsaturated fatty acids and bile acids as potent markers were closely related to the severity and chronicity of drug-induced liver injury patients, respectively. 476 In addition, the distinct metabolic signatures at the acute phase of COVID-19 patients compared to the recovery period, suggesting arginine and tryptophan metabolism as main pathways with a probable link to disease severity.…”

Section: Exploring Phenotype Signaturesmentioning

confidence: 99%

Small molecule metabolites: discovery of biomarkers and therapeutic targets

Qiu

Cai

et al. 2023

Sig Transduct Target Ther

154

View full text Add to dashboard Cite

Metabolic abnormalities lead to the dysfunction of metabolic pathways and metabolite accumulation or deficiency which is well-recognized hallmarks of diseases. Metabolite signatures that have close proximity to subject’s phenotypic informative dimension, are useful for predicting diagnosis and prognosis of diseases as well as monitoring treatments. The lack of early biomarkers could lead to poor diagnosis and serious outcomes. Therefore, noninvasive diagnosis and monitoring methods with high specificity and selectivity are desperately needed. Small molecule metabolites-based metabolomics has become a specialized tool for metabolic biomarker and pathway analysis, for revealing possible mechanisms of human various diseases and deciphering therapeutic potentials. It could help identify functional biomarkers related to phenotypic variation and delineate biochemical pathways changes as early indicators of pathological dysfunction and damage prior to disease development. Recently, scientists have established a large number of metabolic profiles to reveal the underlying mechanisms and metabolic networks for therapeutic target exploration in biomedicine. This review summarized the metabolic analysis on the potential value of small-molecule candidate metabolites as biomarkers with clinical events, which may lead to better diagnosis, prognosis, drug screening and treatment. We also discuss challenges that need to be addressed to fuel the next wave of breakthroughs.

show abstract

Metabolomics and cellular altered pathways in cancer biology: A review

Bhardwaj,

Siwach,

Sachdeva

2024

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Cancer is a deadly disease that affects a cell's metabolism and surrounding tissues. Understanding the fundamental mechanisms of metabolic alterations in cancer cells would assist in developing cancer treatment targets and approaches. From this perspective, metabolomics is a great analytical tool to clarify the mechanisms of cancer therapy as well as a useful tool to investigate cancer from a distinct viewpoint. It is a powerful emerging technology that detects up to thousands of molecules in tissues and biofluids. Like other “‐omics” technologies, metabolomics involves the comprehensive investigation of micromolecule metabolites and can reveal important details about the cancer state that is otherwise not apparent. Recent developments in metabolomics technologies have made it possible to investigate cancer metabolism in greater depth and comprehend how cancer cells utilize metabolic pathways to make the amino acids, nucleotides, and lipids required for tumorigenesis. These new technologies have made it possible to learn more about cancer metabolism. Here, we review the cellular and systemic effects of cancer and cancer treatments on metabolism. The current study provides an overview of metabolomics, emphasizing the current technologies and their use in clinical and translational research settings.

show abstract

Metabolic signatures of hepatolithiasis using ultra-high performance liquid chromatography-tandem mass spectrometry

Cited by 3 publications

References 40 publications

Hepatolithiasis: Epidemiology, presentation, classification and management of a complex disease

Hepatolithiasis: Epidemiology, presentation, classification and management of a complex disease

Small molecule metabolites: discovery of biomarkers and therapeutic targets

Metabolomics and cellular altered pathways in cancer biology: A review

Contact Info

Product

Resources

About